Escherichia coli O157:H7 sepsis following fecal microbiota transplant in an IgA-deficient inflammatory bowel disease patient

Introduction Clostridioides difficile infection(CDI)is a common gastrointestinal illness worldwide,with increased prevalence and worse outcomes in patients with inflammatory bowel disease(IBD)[1].Fecal microbiota transplant(FMT)is an effective treatment for recurrent CDIs(RCDIs)with minimal serious adverse events(SAEs)reported[2].While immunosuppressive medications increase susceptibility to infections,studies have shown that FMT does not increase SAE risk in immunocompromised patients(including IBD patients on immunosuppressive therapy)[3].